SCHEMBL3435645

SCHEMBL3435645

CCOC(=O)CCc1ccc(N2CCN(CC(N)=O)CC2)c(N)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT1 Q99873 1/20 0.49
CYP4F2 P78329 1/20 0.43
CYP4A11 Q02928 1/20 0.43
USP14 P54578 1/20 0.40
ALDH1A1 P00352 2/20 0.39
KDM4E B2RXH2 1/20 0.39
HSD17B10 Q99714 1/20 0.39
BACE1 P56817 1/20 0.39
HRH3 Q9Y5N1 1/20 0.39
LGMN Q99538 1/20 0.39
CYP4Z1 Q86W10 1/20 0.37
ABCC1 P33527 1/20 0.36
PDE3B Q13370 1/20 0.36
PDE3A Q14432 1/20 0.36
P2RY12 Q9H244 1/20 0.36
SIRT2 Q8IXJ6 1/20 0.36
SIRT1 Q96EB6 1/20 0.36
SIRT3 Q9NTG7 1/20 0.36
TMEM97 Q5BJF2 2/20 0.36
SIGMAR1 Q99720 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3436290 0.90 CYP4F2 (0.44) PRMT1CYP4F2CYP4A11USP14ALDH1A1
SCHEMBL3436294 0.78 MAPT (0.43) USP14ALDH1A1KDM4E
SCHEMBL3434265 0.77 KDM4E (0.49) PRMT1ALDH1A1KDM4EHSD17B10
SCHEMBL3436291 0.76 ITGB3 (0.43)
SCHEMBL14000066 0.76 MAPT (0.46) PRMT1ALDH1A1KDM4EHSD17B10
SCHEMBL3862461 0.74 CYP4F2 (0.61) CYP4F2CYP4A11HRH3CYP4Z1PDE3B
SCHEMBL3435121 0.74 USP8 (0.47) PRMT1ALDH1A1KDM4EHSD17B10
SCHEMBL6982335 0.73 CYP4F2 (0.59) CYP4F2CYP4A11HRH3CYP4Z1PDE3B
SCHEMBL3436575 0.73 MAPT (0.48) PRMT1ALDH1A1KDM4E
SCHEMBL12238292 0.72 CYP4F2 (0.55) CYP4F2CYP4A11ALDH1A1KDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163746-B2 Azolecarboxamide derivative ASTELLAS PHARMA INC. (JP) 2012-04-24 US disclosed
US-20090286766-A1 AZOLECARBOXAMIDE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2009-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286766-A1 AZOLECARBOXAMIDE DERIVATIVE GPR17, NTRK1, TRPV1 PRMT1 2422/4885CYP4F2 2507/4885CYP4A11 2619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.